A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects
Completed · Phase 1
Conditions studied: Safety Evaluation of Escalating Doses
In brief
This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 in healthy subjects.
Key facts
- Study ID
- NCT01485146
- Run by
- Esperion Therapeutics, Inc.
- People needed
- 24
- Starts
- 2011-10-25
- Expected to finish
- 2012-01-25
- Last updated by the study team
- 2019-03-28
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
Where it is running
- Jasper Clinic, Inc. — Kalamazoo, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.